← Eichor
Study identifier: NCT06216002 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Incidence of Residual Neuromuscular Blockade in Fraility in OncoGynae Surgery

Condition: Frailty · Neuromuscular Blockade · General Anesthetic Drug Adverse Reaction  ·  Sponsor: Mahidol University

PhaseNA
Planned participants622
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Frailty among patients undergoing surgery is strongly associated with an elevated risk of adverse perioperative outcomes, heightened incidence of postoperative complications, increased mortality rates, and prolonged hospital length of stay. Our focus centers on investigating the frailty index in the context of complications experienced by patients undergoing oncologic gynecology surgery. The principal objective of this research is to elucidate the extent to which residual neuromuscular blocking agents are linked to frailty.

This description comes directly from the study's public registry record.

Talk to the study team

Patchareya Nivatpumin, M.D.  ·  +66896662187  ·  patchareya.niv@mahidol.ac.th

Jitsupa Nithiuthai, M.D.  ·  +66661466594  ·  jitsupa.nit@mahidol.ac.th

Always discuss trial participation with your own doctor first.

Locations (1)

Anesthesiology department, Siriraj hospital, Mahidol UniversityBangkok, Bangkok, ThailandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06216002